Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer

Trial Profile

Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 21 Jan 2017 Results (Data cut off August 2015; n=787) of interim analysis assessing safety and efficacy of regorafenib, presented at the 2017 Gastrointestinal Cancers Symposium
    • 06 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Sep 2016 Planned primary completion date changed from 1 Mar 2021 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top